亚微乳

摘要： 目的:优化香茅醇亚微乳的制备工艺.方法:采用高效液相色谱法测定香茅醇亚微乳中的香茅醇含量;采用高速剪切分散-高压均质法制备香茅醇亚微乳,以离心稳定常数(ke)、粒径为指标,对其处方及工艺进行优化并进行验证;测定所得制剂的载药量的包封率.结果:香茅醇检测质量浓度的线性范围为4～64μg/mL(R 2=0.9999);精密度、稳定性(24 h)、重复性试验的RSD均小于3％;加样回收率为97.64％～101.97％(RSD=2.28％,n=3)、97.71％～99.50％(RSD=1.29％,n=3)、96.87％～101.48％(RSD=2.86％,n=3).最优处方为大豆油+中链甘油三酯(1:1,g/g)总质量3.75 g,1.2％大豆磷脂0.6 g,胆固醇0.06 g,香茅醇1.25 g,0.6％油酸钠0.3 g,15-羟基硬脂酸聚乙二醇酯0.75 g,泊洛沙姆1880.75 g,加水至50 mL.最优工艺为于4°C下以13000 r/min高速剪切5 min制得初乳后,经稀盐酸调pH至7,再以600 Bar高压均质5 min.按最优处方及工艺制备的3批香茅醇亚微乳的平均粒径为(91.05±0.26)nm,多分散系数为(0.20±0.01),Zeta电位为(-30.86±0.39)mV,ke值为9.23,香茅醇的平均含量为(100.21±0.01)％;载药量为(2.4817±0.0007)mg/mL,包封率为(99.27±0.03)％.结论:优化所得处方及工艺稳定、可行.

摘要： 目的:探讨紫苏醇亚微乳剂(perillyl alcohol of submicron emulsion,POH-SE)对人乳腺癌细胞MDA-MB-435s的增殖抑制作用及其机制.方法:以紫苏醇溶液(perillyl alcohol,POH-SOL)为对照,不同浓度(0、50、100、200、400及800 μmol/L)的POH-SE、紫苏醇壳聚糖亚微乳剂(perillyl alcohol of chitosan submicron emulsion,POH-CSSE)分别作用于细胞;在显微镜下观察细胞形态学变化,采用四甲基偶氮唑盐(MTT)法测其生长抑制率,原位末端标记法(TUNEL)检测细胞凋亡情况,流式细胞术检测细胞生长周期和凋亡率.结果:96 h后,POH-SE组、POH-CSSE组增殖抑制率明显高于POH-SOL组,差异有统计学意义(P＜0.01).随着作用时间的延长,同等药物浓度(800 μmol/L) POH-SE组和POH-CSSE组的增殖抑制率均明显高于POH-SOL组,差异均有统计学意义(P＜0.01),且POH-CSSE比POH-SE具有更好的抑制作用.不同浓度POH-CSSE和POH-SE均能诱导人乳腺癌MDA-MB-435s细胞凋亡,其中POH-CSSE 200、400及800 μmol/L组的凋亡率均明显高于POH-SE组,差异均有统计学意义(P＜0.01).细胞阻滞于G0/G1期,随着POH-SE和POH-CSSE浓度的增加,凋亡细胞增加,呈现剂量依赖模式.结论:POH-SE和POH-CSSE对人乳腺癌细胞MDA-MB-435s的抑制作用较强,其机制可能与其阻断细胞生长周期、诱导细胞凋亡有关.

摘要： The safe,effective and good tastes elaeagnus mollis oil submicron-emulsion was prepared.Furthermore,to study the anti-fatigue activity of elaeagnus mollis oil and its submicron-emulsion.The formulation of elaeagnus mollis oil submicron-emulsion was optimized by orthogonal-design,and the individual components include the emulsifier and the co-emulsifier for preparing are subjected to single factor screening.After treatment,the mice were subjected to weight-bearing swimming test.The blood lactic acid (BLA),serum urea nitrogen (BUN) and hepatic glycogen (LG) were measured immediately after swimming.The best formulation of the submirco-emulsion was as follows:mix emulsifier was 4 ％,oil was 5 ％,glycerol was 4 ％,distilled water 76 ％,potassium sorbate 1％ and sucrose 10 ％.The loading swim time and the levels of BLA,BUN,LG in middle dose group were remarkably changed when compared with that of the control group (P＜ 0.05).While there was no significant difference in the loading swim time and three biochemical indicators between the high/low-dose group and the control group.The clearance ratio of BLA and BUN in middle dose group were apparently higher than the control group.Conclusion:A new,safe,high bioavailability of elaeagnus mollis oil submicron-emulsion was developed successfully.Elaeagnus mollis oil and its submicron-emulsion has the effect of inhibiting the accumulation of BLA and BUN after exercise,increasing the content of LG,so as to alleviating the physical fatigue of mice.This work would provide a new perspective on developing of elaeagnus mollis oil.%制备一种安全有效,口感好的翅果油亚微乳,并探讨翅果油及其亚微乳抗疲劳活性及机理.以翅果油为原料,通过对乳化剂等组分进行处方筛选、采用正交设计进行工艺优化,制备翅果油亚微乳制剂,并对翅果油及其亚微乳抗疲劳活性进行研究.分别进行小鼠负重游泳实验,记录其力竭游泳时间,测定血乳酸(blood lactic acid,BLA)、血清尿素氮(serum urea nitrogen,BUN)和肝糖原(hepatic glycogen,LG)等指标含量,计算BLA、BUN的清除速率及LG的储备量.翅果油亚微乳的最优处方为:混合乳化剂(卵磷脂、聚甘油脂肪酸酯、单硬脂酸甘油酯)为4％、翅果油5％、甘油为4％,蒸馏水为76％,山梨酸钾为1％,蔗糖为10％.与阴性对照组比较,翅果油中剂量组负重游泳时间、BLA、BUN、LG等指标均具有统计学差异(P＜0.05):高、低剂量组负重游泳时间及三项生化指标的均值略高于阴性对照组.亚微乳组各项指标均优于阴性组、翅果油低、高剂量组.成功研制出一种新型的,吸收好,生物利用度高的翅果油亚微乳.翅果油及其亚微乳具有一定的提高运动耐力,抑制运动后血乳酸和尿素氮积累、增加肝糖原储备的作用,从而达到缓解运动性体力疲劳的作用.

摘要： 目的 优化氨溴索亚微乳储存条件,保证药品理化性质稳定.方法 以粒径和含量为检测指标,对氨溴索亚微乳进行影响因素试验、加速试验和长期试验,考察制剂的稳定性.结果 影响因素试验结果显示,制备的乳剂在各条件下粒径变化不明显,但温度增高时,其含量和pH下降较明显;冻融试验结果显示,乳剂含量变化不明显,但40°C时粒径变化大于60°C时;6个月加速试验和长期试验结果显示,乳剂含量pH下降不明显,粒径略微增加.结论 为确保氨溴索亚微乳注射剂的理化性质稳定,需冷藏储存.

摘要： Objective:To prepare and conduct physicochemical analysis of water-soluble glycyrrhetinic acid freeze-dried powder.Methods:Glycyrrhetinic acid was dissolved in the mixed solvent with chloroform and ethanol,which was used as oil phase.Meanwhile,mannitol was dissolved in water saturated by chloroform,which was used as water phase.High speed homogenizer was utilized to prepare crude emulsion.Next,high pressure homogenization technique was employed to treat the crude emulsion to obtain submicron emulsion.The residual organic solvent was eliminated through vacuum rotary evaporation.Finally,water soluble glycyrrhetinic acid freeze-dried powder was obtained by lyophilization.The emulsification technology used to prepare crude emulsion was optimized by single factor method.Results:The optimized conditions were the volume ratio of oil phase and water phase (15％),glycyrrhetinic acid concentration (155 mg· mL-1),emulsification times (18).The watersoluble glycyrrhetinic acid freeze-dried powder was dispersed well in water and opalescent and there was no visible particles;its mean particle size was 241.1 nm with regular rod-like structure observed through scanning electron microscope;the water solubility of water-soluble glycyrrhetinic acid freeze-dried powder at 37 °C was 23.08 μg· mL-1,which increased about 5 times compared with glycyrrhetinic acid (3.84 μg· mL-1).Conclusion:The particle size of glycyrrhetinic acid can be reduced to nanometer scale by emulsification method and the water solubility of glycyrrhetinic acid can be improved.%目的:制备水溶性甘草次酸冻干粉,并进行理化分析.方法:将甘草次酸溶解于三氯甲烷和乙醇的混合溶剂作为油相,甘露醇溶解于三氯甲烷饱和水溶液作为水相,使用高速匀浆器进行乳化形成油包水型(o/w)粗乳,接着转入高压均质机内乳化得到亚微乳.再利用真空旋转蒸发除去有机溶剂,经冷冻干燥获得水溶性甘草次酸冻干粉.形成粗乳的第一步乳化工艺借助单因素法进行优化.结果:甘草次酸粗乳的最佳制备工艺条件是油相和水相体积比为15％,甘草次酸浓度为155 mg·mL-1,乳化次数为18次;水溶性甘草次酸冻干粉在水中分散良好呈现乳光,没有肉眼可见颗粒;其平均粒径为241.1 nm,扫描电镜下观察呈规则棒状;在37°C水中溶解度为23.08 μg·mL-1,比甘草次酸原粉(3.84 μg·mL-1)提高了大约5倍.结论:乳化法能将甘草次酸粒径减小至纳米范畴,并且提高其水中溶解度.

摘要： 目的:评价12种市售亚微乳制剂的稳定性,并筛选稳定性考察方法.方法:选取市售的12种亚微乳制剂,分别采用高压灭菌(121°C,30 min)、高速离心(4000 r/min,15 min)、加速试验[温度(40±2)°C、相对湿度(75±5)%的条件下放置6个月]3种考察方法对亚微乳的pH、粒径等指标进行测定,通过SPSS 22.0软件进行粒径分布方差、卡方检验并评价3种考察方法的相关性.结果:在稳定性考察方面,12种亚微乳pH值在加速试验后有不同程度下降,平均粒径大于300 nm的亚微乳有6种;9种亚微乳的粒径方差分布在0.05~0.15之间,8种亚微乳卡方检验结果分布在1以下;加速试验后4种亚微乳平均粒径变化大于10 nm.在稳定性考察方法方面,高压灭菌与加速试验皮尔森(Pearson)卡方渐进显著性为0.665>0.05,表明两者无相关性(没有显著性),高压灭菌稳定性结果并不能说明加速试验的结果;高速离心与加速试验Pearson卡方渐进显著性为0.004<0.05,表明高速离心稳定性与加速试验结果有显著相关性.结论:市售亚微乳稳定性评价结果均符合要求;高速离心可在一定程度上代替加速试验.%OBJECTIVE:To evaluate the stability of 12 kinds of submicro emulsion in market,and screen the test method for the stability. METHODS:12 kinds of submicro emulsion in market were selected,high pressure sterilization (121 °C,30 min), high speed centrifugation(4000 r/min,15 min),accelerated test [placing 6 months under temperature of(40±2)°C,relative hu-midity of (75 ± 5)%] were conducted to investigate the pH,particle size and other indexes,and SPSS 22.0 was used to analyze the distribution variance and chi-square test,and investigate the correlation of 3 evaluation methods. RESULTS:In terms of stabili-ty investigation,the pH value of 12 kinds of submicro emulsion decreased to some extent after accelerated test,average particle size of 6 kinds of submicro emulsion samples were greater than 300 nm,the variance of the particle size distribution of 9 kinds ap-peared in 0.05-0.15,the chi-square test results of 8 kinds distributed below 1. The average particle size of 4 kinds of submicro emul-sions changed more than 10 nm after accelerated test. In terms of stability test method,Pearson chi-square progressive significance of high pressure sterilization and accelerated test was 0.665,which was higher than 0.05,indicating there was no correlation (no significance),the stability results of high pressure sterilization can not represent the results of accelerated test;that of high speed centrifugation and accelerated test was 0.004,which was lower than 0.05,indicating stability results between high speed centrifuga-tion and accelerated test results were significantly correlated. CONCLUSIONS:The submicro emulsion in market can meet the re-quirements of stability. To a certain extent,high speed centrifugation can replace the acceleration test.

摘要： Objective:To explore the anti-tumor effect of Tanshinone Ⅱ A microemulsion and to research its reversal effect of multidrug resistance on SMMC-7721/VCR tumor.Methods The human hepatocellular carcinoma cell line SMMC-7721 and human hepatocellar carcinoma drug-resisitant cell line SMMC-7721/VCR were cultured in vitro.Each cell was divided three groups:experimental group (cell suspension + 3 kinds of anti-tumor drugs),negative control group (cell suspension + culture) and blank control group (culture).Tanshinone Ⅱ A microemulsion and Tanshinone Ⅱ A in five concentrations (0.5,1.0,2.0,4.0,8.0 μg · mL-1) intervention SMMC-7721 cells.The inhibition effect of Tanshinone Ⅱ A microemulsion of 0.5,1,2,4,8 μg · mL-1 in 24 h and 48 h on SMMC-7721 cell proliferation was tested by MTT assay.The IC50 of VCR,CDDP,5-fluorouracil(5-Fu) for the cell of SMMC-7721,SMMC-7721/VCR were determined by MTT assay.The IC50 of VCR,CDDP,5-Fu for the SMMC-7721/VCR after intervention with Tanshinone Ⅱ A microemulsion were determined also by MTT assay.The sensitivity change and drug reversal effect of Tanshinone Ⅱ A microemulsion before and after intervention on the SMMC-7721/VCR cell line was investigated by MTT assay.Results The inhibition rate after intervention with Tanshinone Ⅱ A microemulsion on SMMC-7721 cells for 48 h were 47.93％,55.92％,66.34％,95.61％.Accordingly,the inhibition rate of Tanshinone Ⅱ A were 38.83％,49.31％,58.24％,82.46％.The half inhibitory concentration were (0.67 ±0.32),(1.91 ±0.53) μg · mL-1,respectively.The difference had statistical significance (all P ＜ 0.01).With the increase of concentration,the inhibition rate increased of Tanshinone Ⅱ A microemulsion on SMMC-7721 cell with dose dependence and time dependence.When the concentration of Tanshinone ⅡA and its microemulsion for 0.5 ug · mL-1,on SMMC-7721 cells and SMMC-7721/VCR cell growth inhibition rate were 9.53％,7.74％,both less than 10％ and no obvious toxic effect,so concentration of 0.5 μg · mL-1 was choosed as liver cancer drug resistant safety experiment dose.When 0.5 ug · mL-1 Tanshinone Ⅱ A microemulsion was intervention on SMMC-7721/VCR cell,VCR to SMMC-7721/VCR half inhibitory concentration was from (12.27 ±0.84) ug · mL-1 to (3.25 ±0.14) ug · mL-1.Reverse ratio is 3.78.Half inhibitory concentration of CDDP on SMMC-7721/VCR cell is from (20.42 ± 0.18) μg · mL-1 to (6.98 ±0.99) μg · mL-1,reverse ratio is 2.93.Half inhibitory concentration of 5-FU on SMMC-7721/ VCR cell is from (35.21 ± 0.68) μg · mL-1 to (18.27 ± 2.18) ug · mL-1;reverse ratio is 1.93.Compared with the effect on SMMC-7721 ceils,VCR,CDDP,5-FU effect on SMMC-7721/VCR cells had significant difference (P ＜0.01).Compared with the effect on SMMC-7721/VCR cell which was dealed by Tanshinone Ⅱ A microemulsion,VCR,CDDP,5-FU effect on SMMC-7721/VCR cells had significant difference (P ＜ 0.01).Conclusion The Tanshinone Ⅱ A submicroemulsion can inhibit the growth of SMMC-7721 cells and SMMC-7721/VCR cells.The Tanshinone Ⅱ A submicroemulsion can partially reverse the multidrug resistance of SMMC-7721/VCR in vitro.%目的 研究丹参酮Ⅱ A亚微乳的抗肿瘤作用及逆转人肝癌耐药细胞株SMMC-7721/VCR肿瘤的多药耐药性的作用.方法 体外培养人肝癌细胞SMMC-7721及SMMC-7721/VCR细胞,每种细胞都分为3组:实验组(细胞悬液+3种化疗药)、阴性对照组(细胞悬液+培养液)和空白对照组(培养液).丹参酮Ⅱ A亚微乳和丹参酮Ⅱ A以5个浓度(0.5,1.0,2.0,4.0,8.0 μg· mL-1)对SMMC-7721细胞作用,用四甲基偶氮唑蓝(MTT)法,检测丹参酮ⅡA和丹参酮Ⅱ A亚微乳作用24,48 h对SMMC-7721细胞的抑制作用;同时,检测长春新碱、顺铂、5-氟尿嘧啶(5-FU)这3种化疗药对SMMC-7721、SMMC-7721/VCR细胞株及丹参酮Ⅱ A亚微乳干预后的SMMC-7721/VCR细胞株的半数抑制浓度(IC5o),观察丹参酮Ⅱ A亚微乳干预前后耐药细胞株的药敏性变化及药物逆转效果.结果 前4个浓度丹参酮Ⅱ A亚微乳对SMMC-7721细胞作用48 h的抑制率分别为47.93％,55.92％,66.34％,95.61％,IC50为(0.67±0.32)μg· mL-1;丹参酮Ⅱ A对其的抑制率分别为38.83％,49.31％,58.24％,82.46％,IC50为(1.91 ±0.53)μg·mL-,两者相比差异均有统计学意义(均P＜0.01).丹参酮Ⅱ A亚微乳对SMMC-7721细胞的抑制率随着浓度的增加而逐渐升高,呈剂量依赖性和时间依赖性.0.5μ g·mL-1丹参酮Ⅱ A亚微乳浓度对SMMC-7721细胞及SMMC-7721/VCR细胞的生长抑制率分别为9.53％,7.74％(均＜10％),说明两者均无明显毒性作用.0.5μg·mL-1丹参酮Ⅱ A亚微乳干预SMMC-7721/VCR细胞,长春新碱对SMMC-7721/VCR的半数抑制浓度由(12.27 ±0.84) μg·mL-1降为(3.25±0.14) μ.g·mL-1,逆转倍数为3.78.顺铂对SMMC-7721/VCR的半数抑制浓度由(20.42-0.18) μg·mL-降为(6.98±0.99)μg·mL-1,逆转倍数是2.93;5-FU对SMMC-7721/VCR的半数抑制浓度由(35.21±0.68)μg· mL-1降为(18.27±2.18)μg·mL-1,逆转倍数分别为1.93.与对SMMC-7721细胞作用相比,长春新碱、顺铂、5-FU对SMMC-7721/VCR细胞作用差异均有统计学意义(P＜0.01).与丹参酮Ⅱ A亚微乳干预后的SMMC-7721/VCR细胞作用相比,长春新碱、顺铂、5-FU对SMMC-7721/VCR细胞作用差异均有统计学意义(P＜0.01).结论 丹参酮Ⅱ A亚微乳可以抑制SMMC-7721细胞及SMMC-7721/VCR细胞的生长;丹参酮Ⅱ A亚微乳在体外能够部分逆转SMMC-7721/VCR的多药耐药性.

摘要： 目的:本实验将7-乙基-10-羟基喜树碱(SN38)制备成亚微乳(SN38-SME),并对其性质进行体外表征.方法:采用高压均质法制备SN38-SME,并采用激光粒度仪、透射电镜考察亚微乳的形态,葡聚糖凝胶柱法测量包封率、载药量.结果:SN38-SME呈类球形,粒径在100-200nm,稳定性好,包封率、载药量较高.结论:本实验成功制备了SN38-SME,具有一定的实用价值.

摘要： 目的 探讨氨溴索亚微乳的理化性质.方法 在氨溴索亚微乳处方和制备工艺的基础上,对乳剂类型、粒径、pH、黏度等理化性质进行考察.结果 制备的乳剂外观为乳白色,3批样品的粒径分别为169.9,170.0,166.8 nm,平均pH为8.12,8.19,8.23,25°C时黏度为(1.9±0.1)mPa·s.结论 氨溴索亚微乳注射剂的理化性质稳定,符合静脉注射要求.

摘要： 介绍中药乳剂不同给药途径的研究现状及进展,为中药乳剂的进一步研究开发提供参考依据.检索近年中药乳剂相关文献293篇,分析其内容和数量,对中药注射微乳的研究关注度比较高.近年来中药乳剂研究的主要内容为中药静脉注射微乳、经皮给药中药乳剂、鼻腔给药中药乳剂与眼部给药中药乳剂.

摘要： 本文旨在制备一种新型的依托泊苷-槐糖脂亚微乳并考察槐糖脂对吐温-80的替代效果.采取高压均质法制备亚微乳,通过单因素实验考察影响亚微乳质量的因素,其中,以平均粒径和Zeta电位为表征指标,采用HPLC法测定依托泊苷的载药量.实验结果表明,当高压均质次数为8次,压力为800bar时可以得到粒径在200nm以下且电位在25mv以上的稳定的亚微乳.依托泊苷-槐糖脂亚微乳不仅比传统亚微乳毒副作用更低,而且载药量提高了112.6％.结果证明,槐糖脂替代吐温-80的新型亚微乳是可行的,具有很好的市场前景.

摘要： 目的：通过星点设计-效应面法优化亚微乳佐剂处方.方法：以浊度法测定角鲨烯所需乳化剂HLB值;以水数法测定卵磷脂和Solutol HS 15的HLB值;以卵磷脂+Solutol HS 15用量(X1)、卵磷脂与Solutol HS 15用量比值(X2)、油酸钠用量(X3)为考察因素,以平均粒径和浊度的综合指标OD值为考察指标,建立二次多项式模型,根据模型绘制效应面和等高线图,确定优化处方,最后进行验证.结果：角鲨烯所需乳化剂HLB值约为10;卵磷脂的HLB值为7.4,SolutolHS 15的HLB值为12.5;优化处方中卵磷脂为0.6％(w/v),Solutol HS 15为0.6％(w/v),油酸钠为0.025％(w/v),优化处方指标的预测值和测定值非常接近,二次多项式模型置信度高.结论：采用星点设计-效应面法,得到了二次多项式模型,实现了亚微乳佐剂的处方优化.

摘要： 目的:筛选黄芩提取物磷脂复合物适宜的鼻腔给药剂型.方法:采用猪鼻粘膜透过性能、鼻黏膜刺激性等评价手段对溶液剂、亚微乳、原位凝胶等5种不同剂型的优选.结果:亚微乳表观渗透系数最大,而刺激性最小,且具有较高的载药量,能够满足鼻腔给药的要求.结论:亚微乳是黄芩提取物磷脂复合物鼻腔给药制剂的最佳剂型.

摘要： 为观察亲脂性药物纳米载体的细胞转运过程、研究细胞动力学行为、考察处方因素对载体转运的影响，指导具体药物载体的选择和设计。rn 本文选用了亲脂性荧光染料6-香豆素为模型药物，制备了脂质体、聚乳酸-乙醇酸共聚物(PLGA)纳米粒、亚微乳、磷脂混合胶束五种纳米载体，考察了血清对其粒径、电位和药物释放的影响。利用6-香豆素荧光淬灭试剂比较了不同载体的细胞膜吸附和细胞内化差异，并定量研究了人宫颈癌HeLa细胞对不同载体的摄取及消除过程，结合胞内分布影像资料，总结了细胞消除动力学规律。考察了给药浓度、载体类型对细胞内化的影响，特别是对处方因素对亚微乳细胞摄取的影响进行了研究。最后，以紫杉醇为治疗药物，使用MTT法比较了几种载体的抗肿瘤活性。

摘要： 本发明提供一种白藜芦醇亚微乳及其制备方法，其中白藜芦醇亚微其由活性成分白藜芦醇、脂质、乳化剂、助乳化剂和稳定剂组成。本发明提供的一种白藜芦醇亚微乳稳定性高，热水分散后呈全透明，低温不析出，可与化妆品配方任意互配；该制备方法简单可控，重复性好。

摘要： 本发明涉及一种含有维生素A或其衍生物和维生素E或其衍生物的眼用微乳/亚微乳原位凝胶制剂及其制备方法。该微乳制剂由维生素A或其衍生物和维生素E或其衍生物、油相、乳化剂、增稠剂、等渗调节剂、抑菌剂、pH调节剂、纯化水配制，经剪切-高压均质工艺制备而成。本发明微乳/亚微乳原位凝胶制剂外观呈半透明且有淡蓝色乳光，pH值为5.0-9.0，乳滴平均粒径小于200nm，90％粒径累积值小于等于500nm。本发明制剂在体外为流动性很好的低粘度流体，滴入眼内后很快形成水凝胶，从而增加药物的眼内滞留时间提高生物利用度，且具有对眼部无刺激性及毒副作用，制剂质量稳定等优点。

摘要： 本发明涉及一种亚微乳修复原液组合物的制备方法及包含其的化妆品组合物，所述修复原液组合物包含寡肽‑3、寡肽‑1、Indolicidin或其类似物、Cathelicidin‑BF、透明质酸、甘油、貂油、卵磷脂、辛烯基琥珀酸淀粉钠、脂肪醇聚氧乙烯醚、羟乙基纤维素、丙二醇/双(羟甲基)咪唑烷基脲/羟苯甲酯/碘丙炔醇丁基氨甲酸酯等。所述亚微乳修复原液具有保湿修复、抗菌祛痘功效。该修复原液组合物可促进表皮组织内多种细胞的生长分裂，并促进胶原蛋白生长，修复老化胶原弹性纤维，恢复肌肤活力，特别是对痘印、光疗、烫伤等多种表皮创伤修复效果显著。

摘要： 本发明涉及缓释药物制备技术领域，具体来说是一种吡柔比星载药明胶亚微乳材料及其制备方法和应用，本发明先制备得到了明胶水相物料A，再与油相物料B共混，制备得到了W/O型空白明胶物料C，通过采用W/O型空白明胶物料C对吡柔比星进行包覆；吡柔比星由于其与W/O型空白明胶物料C的相容性较差，因此包覆前，将吡柔比星溶解于体积分数为5％的葡萄糖溶液中，通过在葡萄糖溶液的作用下，实现吡柔比星外包覆W/O型空白明胶物料C，继而得到结构稳定的吡柔比星明胶载药亚微乳材料。本发明不仅制备得到了一种吡柔比星明胶载药亚微乳材料，而且吡柔比星明胶载药亚微乳材料能够被应用于制备缓释抗肿瘤药物中。

摘要： 本发明提供一种白藜芦醇亚微乳及其制备方法，其中白藜芦醇亚微其由活性成分白藜芦醇、脂质、乳化剂、助乳化剂和稳定剂组成。本发明提供的一种白藜芦醇亚微乳稳定性高，热水分散后呈全透明，低温不析出，可与化妆品配方任意互配；该制备方法简单可控，重复性好。

摘要： 本发明公开了1,8‑桉叶油素自微乳和亚微乳给药系统及其制备方法和应用，1,8‑桉叶油素自微乳和亚微乳给药系统，包括1,8‑桉叶油素、由乳化剂和助乳化剂组成的混合溶液和双蒸水，所述1,8‑桉叶油素与由乳化剂和助乳化剂组成的混合溶液的质量比为3:7～27，所述混合溶液的乳化剂和助乳化剂的质量比为1:1～3。其制备方法为将1,8‑桉叶油素、乳化剂和助乳化剂混合均匀，在搅拌状态下加入双蒸水，得成品。应用于制备治疗心脑血管疾病药物。本发明中的1,8‑桉叶油素自微乳和亚微乳给药系统可以获得适宜的临床应用方式，拓展了1,8‑桉叶油素在临床上的应用。

摘要： 本发明涉及一种含有维生素A或其衍生物和维生素E或其衍生物的眼用微乳/亚微乳原位凝胶制剂及其制备方法。该微乳制剂由维生素A或其衍生物和维生素E或其衍生物、油相、乳化剂、增稠剂、等渗调节剂、抑菌剂、pH调节剂、纯化水配制，经剪切－高压均质工艺制备而成。本发明微乳/亚微乳原位凝胶制剂外观呈半透明且有淡蓝色乳光，pH值为5.0－9.0，乳滴平均粒径小于200nm，90％粒径累积值小于等于500nm。本发明制剂在体外为流动性很好的低粘度流体，滴入眼内后很快形成水凝胶，从而增加药物的眼内滞留时间提高生物利用度，且具有对眼部无刺激性及毒副作用，制剂质量稳定等优点。

摘要： 本发明提供了一种泮托拉唑钠亚微乳冻干制剂及其制备方法，该泮托拉唑钠亚微乳冻干制剂主要是由以重量份计的以下组分制成：泮托拉唑钠1－10份、生物降解聚合物5－50份、乳化剂1－20份、骨架支持剂5－40份、稳定剂1－20份。

摘要： 本发明涉及一种含有环孢素A的眼用微/亚微乳原位凝胶制剂及其制备方法，该制剂由环孢素A、油相、乳化剂、助乳化剂、增稠剂、等渗调节剂、抑菌剂、pH调节剂、纯化水配制，经剪切一高压均质工艺制备而成。其特点在于采用安全、无刺激性的非离子表面活性剂聚氧乙烯蓖麻油、聚氧乙烯氢化蓖麻油、吐温或磷脂等作为乳化剂；具有离子和/或pH敏感特性的高分子材料作为增稠剂。本发明微乳原位凝胶制剂乳滴平均粒径小于200nm，90％粒径累积值不大于500nm；在体外为流动性很好的低粘度流体，滴入眼内后很快形成水凝胶，从而增加药物的眼内滞留时间和生物利用度，具有对眼部无刺激性及毒副作用，制剂质量稳定等优点。

摘要： 本发明属于疫苗的水包油乳液佐剂领域，涉及一种浓缩的水包油型亚微乳佐剂及其制备方法。在优选的技术方案中，亚微乳佐剂为2、3、4、6、8倍浓度的MF59。发明制备的浓缩的微乳佐剂相对稳定，佐剂粒径受制备浓度的影响小，可用作疫苗佐剂。在使用时可以按需稀释，提高设备利用率，降低生产成本。